Cost-utility of add-on Omalizumab in difficult-totreat allergic asthma in Italy

European Annals of Allergy and Clinical Immunology

Volumn 43, Issue 2, 2011, Pages 45-53

  Dal Negro, Roberto W ^a,b   Pradelli, L ^c   Tognella, S ^a   Micheletto, C ^a   Iannazzo, S ^c  

^a Ospedale   (Italy)

^b Centro Nazionale Studi Farmacoeconomia e Farmacoepidemiologia Respiratoria CESFAR   (Italy)

^c AdRes HE and OR   (Italy)

Author keywords

Allergic asthma; Cost utility; Difficult to treat asthma; Effectiveness; Health care costs; Omalizumab

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETAMETHASONE; BUDESONIDE; FLUTICASONE; FORMOTEROL; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; MONTELUKAST; MOXIFLOXACIN; OMALIZUMAB; PREDNISONE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; COST UTILITY ANALYSIS; DRUG COST; DRUG MECHANISM; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH STATUS; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MALE; QUALITY OF LIFE;

ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; ITALY; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 79954503591     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dal Negro RW, Micheletto C, Tosatto R, et al. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respir Med 2007, 101:2511-9.
2. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008, 372:1073-87.
3. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children (Cochrane Review). The Cochrane Library Issue. Vol 2. Chichester, United Kingdom:Wiley; 2005.
4. FDA Omalizumab Product Approval Information Sheet 20/06/2003.
5. Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008, 102:1371-8.
6. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J, 2001; 18: 254-61.
7. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med, 2001; 164: S12-7.
8. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy, 2004; 59: 709-17.
9. Diukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-93.
10. Ayers JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy, 2004; 59: 701-8.
11. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy, 2004; 34: 632-8.
12. Humbert M, Beasley R, Ayers J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma whoa are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy, 2005; 60: 309-16.
13. Dal Negro R, Zoccatelli O, Pomari C, Turco P, Girelli-Bruni E - Gestione automatizzata di alcuni flussi informativi nell'ambito della patologia respiratoria. 7th National Congress SIFPR, 1984, pagg 1007-1022, proceedings.
14. Tognella S, Dal Negro RW. Omalizumab: una risposta terapeutico-gestionale per il controllo dell'asma grave resistente. It J Chest Dis, 2007; 61: 390-4.
15. Regional DRG Tariffs. Aggiornamento del tariffario per la remunerazione delle prestazioni di assistenza Ospedaliera. Regione Veneto. Deliberazione della Giunta n. 916 del 28-03-2006.
16. Regional Specialist Tariffs. Nomenclatore Tariffario Regionale delle prestazioni di assistenza specialistica ambulatoriale: aggiornamento tariffe di cui alla D.G.R. n.61 del 21.01.05. Regione Veneto. Deliberazione della Giunta n. 917 del 28-03-2006.
17. Garattini L, Castelnuovo E, Lanzeni D, Viscarra C. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmeconomia e percorsi terapeutici, 2003; 4(2): 109-14.
18. Italian Drugs Formulary. Informatore Farmaceutico - 68a edizione 2008. Elsevier Masson, 2008.
19. Off-Patent Drugs Reference Price System. Lista di trasparenza dei medicinali inseriti nell'elenco dei farmaci equivalenti (Legge 178/2002) con i relativi prezzi di riferimento aggiornati al 17 novembre 2008. http://www.agenziafarmaco.it/PREZ_RIMB_MER/prez_rimb_mer021.html Last accessed December 2008.
20. National Hospital Discharge Database. Statistiche sui ricoveri ospedalieri http://www.ministerosalute.it/programmazione/sdo/ric_informazioni/default.jsp. Last accessed December 2008.
21. Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes, 2005;3:56.
22. Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc, 2007;82(5):575-82.
23. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-42.
24. WHO. CHOosing Interventions that are Cost/Effective (WHO-CHOICE), 2000. Available online at http://www.who. int/choice/costs/CER_levels/en/index.html Last accessed in December 2008.
25. National Istitute of Statistics - ISTAT. Serie storiche del PIL e dei principali aggregati (Anni 1970-2007). http://www.istat.it/conti/Last accessed in December 2008.